Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases.
Level 5 - mechanism / opinion, no new human data
Animal experimental study in hamsters and mice
PubMed 37094549 · doi:10.1016/j.biopha.2023.114754
What was done
High-fat diet-fed hamsters and ApoE (-/-) mice were treated with berberine or metformin to compare therapeutic efficacy across metabolic parameters including fatty liver, systemic inflammation, atherosclerosis, hyperlipidemia, obesity, and blood glucose. The study also evaluated gut microbiota composition and intestinal bile acid changes as potential mechanisms.
What was found
The abstract reports no numerical values, exact effect sizes, or statistical metrics. Qualitatively, both berberine and metformin exhibited similar effects on reducing fatty liver, inflammation, and atherosclerosis. Berberine was more effective than metformin at alleviating hyperlipidemia and obesity, whereas metformin was superior for blood glucose control. Differences in gut microbiota modulation and bile acid composition were associated with these divergent effects.
Why it matters
The findings suggest distinct metabolic profiles for berberine and metformin in animal models, supporting further clinical evaluation of berberine specifically for metabolic disease phenotypes characterized by obesity and dyslipidemia.
Limits
The study was conducted entirely in rodent models (hamsters and genetically modified mice) and cannot establish human clinical efficacy. The abstract provides no sample sizes, dosages, treatment durations, or quantitative outcome data.
Cited by
- supports Berberine drops blood sugar and HbA1c in human randomized controlled trials and is similar in function to metformin.